Mark Schildkraut is Associate General Counsel-IP and Worldwide Cybersecurity Counsel at Becton, Dickinson and Company (BD), a Fortune 500 medical device and instrumentation technology company that develops, manufactures and sells medical devices, instrument systems and reagents.

Mark has responsibility for and leads a team of IP associates that handles intellectual property matters concerning BD’s Pharmaceutical Systems, Diabetes Care and Medication Management Solutions business units.  These matters include patent and trade secret protection, drafting and negotiating technology and commercial agreements, product clearance and IP litigation.  

Mark is also responsible for establishing legal strategy and counsel on trade secrets as well as enforcement issues relating to the infiltration of BD’s information network and product offerings and exfiltration of BD’s sensitive information.  Particularly noteworthy was Mark’s involvement in BD v. Maniar and US v. Maniar, resulting in the guilty plea of two counts of theft and attempted theft of trade secrets.  He has also been involved with criminal prosecutions in Utah and Illinois, as well as civil enforcement in California and China.

Mark has been an associate with BD’s Legal Department since 2005.  

Prior to joining BD, Mark was an associate at Kaye Scholer LLP and Morgan & Finnegan LLP, focusing on patent litigation, IP clearance and prosecution matters.  Mark received his J.D. from Fordham University’s School of Law and a B.S. in Electrical Engineering from the State University of New York at Buffalo.